Navigation Links
Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting
Date:9/27/2010

Newtown, PA, September 27, 2010 Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii. In vivo studies show that Ex-RAD, upon oral administration, produced a significant increase in survival versus placebo-treated groups in mice exposed to lethal whole body irradiation (WBI), for both prophylactic pre-treatment and mitigation post-treatment. Ex-RAD is the only known oral radioprotectant that has shown such activity in animal model systems.

Collectively, these presentations demonstrate the ability of Ex-RAD to provide radioprotective benefit by injection and oral delivery, an in-depth understanding of the kinetics and metabolism of Ex-RAD, and radioprotective benefit to human bone marrow, as well as the gastrointestinal and hematopoietic systems in mice.

Onconova, a biopharmaceutical company developing novel chemical entities to treat cancer and protect normal cells, is developing Ex-RAD, a novel radioprotectant with potential utility in bio-defense or bio-terrorism, which could prove useful as a prophylactic agent for first-responder protection from the harmful effects of radiation from nuclear accidents or weapons of mass destruction (WMD).

These presentations result from an on-going Onconova collaboration among investigators at a number of institutions: AFRRI, (The Armed Forces Radiobiology Research Institute) a part of the Uniformed Services University of the Health Sciences (USUHS); Georgetown University, Department of Biochemistry and Molecular & Cellular Biology; Long Island University, Arnold & Marie Schwartz College of Pharmacy; and the Department of Oncological Sciences, Mt. Sinai School of Medicine.

Summary of Oral Ex-RAD Findings

The results from a prophylactic radioprotection study in mice demonstrated that Ex-RAD dosed orally or by injection prior to lethal whole body irradiation (WBI) produced significant enhancement in survival for both Ex-RAD treated groups versus placebo.

Results from the radiomitigation experiment (where the drug is administered after exposure to lethal radiation), using both injection and oral methods of delivery demonstrated that Ex-RAD treated animals had comparably high rates of survival in both groups.

Hence, oral Ex-RAD was found to be effective in both prophylactic pre-treatment and mitigation post-treatment settings.

"Years of collaborative work are resulting in great progress with Ex-RAD in the laboratory and the clinic and Ex-RAD is the focus of several posters and a key presentation within the RSS scientific and educational track," said Manoj Maniar, PhD, Senior Vice President for Product Development of Onconova. "We are very excited to see the acceleration and new developments within radioprotection, specifically in oral prophylaxis and treatment. Ex-RAD holds a unique position among developing products with the potential to benefit people exposed to whole body radiation."

Onconova oral presentation and poster sessions on Ex-RAD at the Radiation Research Society meeting:

Oral Presentation

WEDNESDAY, SEPTEMBER 29, 2010

  • No. MS701 (Mini-Symposium Presentation, 10:15 AM-12:15 PM) Radioprotection and Radiomitigation Properties of Ex-RAD Upon Oral Administration Manoj Maniar1, Ramesh Kumar1, Bo-Hyun Moon2, David Taft3, Kamal Datta2; 1Onconova Therapeutics, Inc., 2Georgetown University, Department of Biochemistry and Molecular & Cellular Biology and Lombardi Comprehensive Cancer Center, 3Long Island University, Arnold & Marie Schwartz College of Pharmacy

Poster Sessions Radiation Protection Protection / Mitigators / Treatment

SUNDAY, SEPTEMBER 26, 2:00 pm-2:45 pm, 2010, Haleakala Foyer

  • PS.1.56 Radioprotection and Radiomitigation Properties of Ex-RAD Upon Oral Administration Manoj Maniar1, Ramesh Kumar1, Bo-Hyun Moon2, David Taft3, Kamal Datta2; 1Onconova Therapeutics, Inc., 2Georgetown University, Department of Biochemistry and Molecular & Cellular Biology and Lombardi Comprehensive Cancer Center, 3Long Island University, Arnold & Marie Schwartz College of Pharmacy

  • PS1.10Recovery from radiation-induced hematopoietic and gastrointestinal sub-syndromes by Ex-RAD in murine model, Sanchita P. Ghosh1, Shilpa Kulkarni1, Michael W. Perkins1, Kevin Hieber1, Ethery Amari1, Kristen Gambles1, Manoj M. Maniar2, Thomas Seed1, and K. Sree Kumar1; 1Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, 2Onconova Therapeutics Inc.

  • PS1.73Radioprotection of human bone marrow by ON 01210.Na (Ex-RAD ) through AKT-mediated signaling pathway Anthony D. Kang1,2, Stephen C.Cosenza1,3, Ramana Reddy1,3, E. Premkumar Reddy1,3 1Fels Institute for Cancer Research and Molecular Biologyand 2Armed Forces Radiobiology Research Institute, 3Department of Oncological Sciences, Mt. Sinai School of Medicine

Poster Sessions Experimental Therapeutics and Translational Research

WEDNESDAY, SEPTEMBER 29, 5:30 PM-6:15 PM, 2010 Haleakala Foyer

  • PS7.64 Disposition of Ex-RAD (ON 01210.Na), a new radioprotectant, in the isolated perfused rat liver model; Chen Ren1, Mitalee Tamhane2, David Taft2, Manoj Maniar1, 1Onconova Therapeutics, Inc., 2Long Island University

  • PS7.20Metabolic disposition of Ex-RAD (ON 01210.Na), a novel radioprotectant Chen Ren1, Mitalee Tamhane2, Glenn Fegley1, David Taft2, Manoj Maniar1; 1Onconova Therapeutics, Inc., 2Long Island University, Brooklyn, NY


'/>"/>

Contact: Katrhyn Morris
kathryn@proncall.com
845-635-9828
PR on Call
Source:Eurekalert

Related medicine news :

1. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
2. Study says therapeutics for trauma patients may not be effective due to an infection
3. Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference
4. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
5. ACS Webinar focuses on drug discovery process for small molecule therapeutics
6. Talecris Biotherapeutics Hires Nimish Shah as Vice President, Federal Government Relations
7. US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
8. JDP Therapeutics, Inc. Appoints Christopher M. Cashman to Board of Directors
9. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
11. FAB-HOMES™ Presents First Passive House Collection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet ... a conversation on the current obstacles facing infection prevention and offer strategies for ... caused by these infections. , The print component of “Fighting Infection” is ...
(Date:3/24/2017)... , ... March 24, 2017 , ... Texas Physical ... can be found at 9618 Huebner Road. The clinic is the group’s 7th location ... Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which opened ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... ) announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center ... in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “Vintage and Harvest ... retired minister and college Bible teacher residing in North Carolina with his wife, Anna ... have blessed them with six grandchildren. David is also the author of “Shadow and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Appliances and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), ... Sunshine Heart Inc. (NASDAQ: SSH ). These companies ... of its prior gains on Thursday, March 23 rd , ... the afternoon, while shares of health care companies in the ...
(Date:3/24/2017)... , March 23, 2017  HealthMine surveys with 9,250 ... revealed that health plan members want help from their ... stay engaged in their health, 2) help closing gaps ... platform for health and 5) relevant, real-time guidance. Meeting ... lowering healthcare costs. A Reason ...
(Date:3/24/2017)... The Board of Directors of Nordic ... 2016 including the complete 2016 Annual Accounts with notes. The ... Nanovector,s website in the section Investor Relations/Reports and presentations/Annual Reports. ... For ... Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: